MedTrace Logo

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

NCT06858332 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2382

Last updated 2025-08-03

No results posted yet for this study

Summary

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Conditions

Interventions

DRUG

Atorvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUG

Simvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUG

Rozuvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUG

Ezetimibe

Ezetimibe

DRUG

Niacin

Niacin

DRUG

Ciprofibrate

Fibrates

DRUG

Fenofibrate

Fibrates

DRUG

Bezafibrate

Fibrates

DRUG

Evolocumab

PCSK9 inhibitor

DRUG

Alirocumab

PCSK9 inhibitor

DRUG

Inclisiran

Small interfering RNA

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06858332 on ClinicalTrials.gov